Svizzera - italiano - Swissmedic (Swiss Agency for Therapeutic Products)

incyte biosciences international sàrl - ponatinibum - compresse rivestite con film - ponatinibum 15 mg per ponatinibi hydrochloridum, excipiens pro compresso haze. - agente antineoplastico - synthetika

Svizzera - italiano - Swissmedic (Swiss Agency for Therapeutic Products)

incyte biosciences international sàrl - ponatinibum - compresse rivestite con film - ponatinibum 45 mg per ponatinibi hydrochloridum, excipiens pro compresso haze. - agente antineoplastico - synthetika

Svizzera - italiano - Swissmedic (Swiss Agency for Therapeutic Products)

incyte biosciences international sàrl - ponatinibum - compresse rivestite con film - ponatinibum 30 mg a ponatinibi hydrochloridum, excipiens pro compresso haze. - agente antineoplastico - synthetika

Unione Europea - italiano - EMA (European Medicines Agency)

incyte biosciences distribution b.v. - ponatinib - leukemia, myeloid; leukemia, lymphoid - antineoplastic agents, protein kinase inhibitors - iclusig is indicated in adult patients withchronic phase, accelerated phase, or blast phase chronic myeloid leukaemia (cml) who are resistant to dasatinib or nilotinib; who are intolerant to dasatinib or nilotinib and for whom subsequent treatment with imatinib is not clinically appropriate; or who have the t315i mutationphiladelphia chromosome positive acute lymphoblastic leukaemia (ph+ all) who are resistant to dasatinib; who are intolerant to dasatinib and for whom subsequent treatment with imatinib is not clinically appropriate; or who have the t315i mutation. vedi sezioni 4. 2 assessment of cardiovascular status prior to start of therapy and 4. 4 situations where an alternative treatment may be considered.

Italia - italiano - AIFA (Agenzia Italiana del Farmaco)

janssen cilag s.p.a. - itraconazolo - itraconazolo

Italia - italiano - AIFA (Agenzia Italiana del Farmaco)

italfarmaco s.p.a. - itraconazolo - itraconazolo

Italia - italiano - AIFA (Agenzia Italiana del Farmaco)

s.f. group s.r.l. - itraconazolo - itraconazolo

Svizzera - italiano - Swissmedic (Swiss Agency for Therapeutic Products)

janssen-cilag ag - itraconazolum - capsule - itraconazolum 100 mg, hypromellosum, macrogolum 20'000, sacchari sphaerae ut saccharum 175.68 mg et maydis amylum, kapselhülle: gelatina, e 127, e 132, e 171 pro capsula. - antifungini - synthetika

Svizzera - italiano - Swissmedic (Swiss Agency for Therapeutic Products)

janssen-cilag ag - itraconazolum - capsule - itraconazolum 100 mg, hypromellosum, macrogolum 20'000, sacchari sphaerae ut saccharum 175.68 mg et maydis amylum, kapselhülle: gelatina, e 127, e 132, e 171 pro capsula. - vulvovaginalcandiosis - synthetika

Svizzera - italiano - Swissmedic (Swiss Agency for Therapeutic Products)

janssen-cilag ag - itraconazolum - soluzione orale - itraconazolum 100 mg, hydroxypropylbetadexum 4 g, acidum hydrochloridum concentratum, propylenglycolum 1.04 g, natrii hydroxidum ad ph, sorbitolum liquidum non cristallisabile corresp. sorbitolum 1981 mg, aromatica (kirsche), ethanolum 0.05 mg, saccharinum natricum, saccharum tostum, aqua purificata ad solutionem pro 10 ml corresp. natrium 5.38 mg. - antifungini - synthetika